| Patient age at transplantation, median, y (range) | 43 (18-61) |
| Donor age at transplantation, median, y (range) | 41 (13-62) |
| Patient sex | |
| Male | 60 |
| Female | 33 |
| Donor-patient histocompatibility | |
| HLA-A–, HLA-B–, and HLA-DR–matched sibling | 92 |
| HLA-A–, HLA-B–, and HLA-DR–matched child | 1 |
| Disease type at transplantation | |
| Good-risk* | 55 |
| Poor-risk† | 38 |
| Splenectomy | |
| Splenectomized patients | 3 |
| Nonsplenectomized patients | 90 |
| CD34 cell dose × 106/kg recipient body weight, median (range) | 6 (1-18) |
| Type of transplant | |
| Peripheral blood stem cell recipients | 44 |
| Marrow recipients | 49 |
| Myeloablative conditioning | |
| Chemotherapy only‡ | 47 |
| Chemotherapy plus total body irradiation1-153 | 43 |
| Chemotherapy plus total marrow irradiation1-155 | 3 |
| GVHD prophylaxis | |
| Methotrexate (days 1, 3, 6, and 11) plus cyclosporine (daily for 6 months)24 | 93 |
| Other | 0 |
| Acute GVHD | |
| Grade 0-1 | 25 |
| Grade 2-41-154 | 68 |
| Chronic GVHD diagnosed by day 365 | |
| None or clinical limited | 38 |
| Clinical extensive1-159 | 47 |
| Not applicable (owing to relapse or death before day 100) | 8 |
| Chimerism status | |
| Full chimera (at least 90% marrow cells of donor origin by day 80) | 86 |
| Unknown | 7 |
| Relapse diagnosed between days 30 and 3651-160 | |
| Yes | 11 |
| No | 82 |
| Death without relapse between days 30 and 365 | |
| Yes | 14 |
| No | 79 |
| Serum IgG level (g/L), median (range) | |
| On day 80 (n = 75)1-164 | 5.4 (2.2-22.6) |
| On day 365 (n = 61)1-164 | 5.8 (1.4-22.4) |
| Patient age at transplantation, median, y (range) | 43 (18-61) |
| Donor age at transplantation, median, y (range) | 41 (13-62) |
| Patient sex | |
| Male | 60 |
| Female | 33 |
| Donor-patient histocompatibility | |
| HLA-A–, HLA-B–, and HLA-DR–matched sibling | 92 |
| HLA-A–, HLA-B–, and HLA-DR–matched child | 1 |
| Disease type at transplantation | |
| Good-risk* | 55 |
| Poor-risk† | 38 |
| Splenectomy | |
| Splenectomized patients | 3 |
| Nonsplenectomized patients | 90 |
| CD34 cell dose × 106/kg recipient body weight, median (range) | 6 (1-18) |
| Type of transplant | |
| Peripheral blood stem cell recipients | 44 |
| Marrow recipients | 49 |
| Myeloablative conditioning | |
| Chemotherapy only‡ | 47 |
| Chemotherapy plus total body irradiation1-153 | 43 |
| Chemotherapy plus total marrow irradiation1-155 | 3 |
| GVHD prophylaxis | |
| Methotrexate (days 1, 3, 6, and 11) plus cyclosporine (daily for 6 months)24 | 93 |
| Other | 0 |
| Acute GVHD | |
| Grade 0-1 | 25 |
| Grade 2-41-154 | 68 |
| Chronic GVHD diagnosed by day 365 | |
| None or clinical limited | 38 |
| Clinical extensive1-159 | 47 |
| Not applicable (owing to relapse or death before day 100) | 8 |
| Chimerism status | |
| Full chimera (at least 90% marrow cells of donor origin by day 80) | 86 |
| Unknown | 7 |
| Relapse diagnosed between days 30 and 3651-160 | |
| Yes | 11 |
| No | 82 |
| Death without relapse between days 30 and 365 | |
| Yes | 14 |
| No | 79 |
| Serum IgG level (g/L), median (range) | |
| On day 80 (n = 75)1-164 | 5.4 (2.2-22.6) |
| On day 365 (n = 61)1-164 | 5.8 (1.4-22.4) |
GVHD indicates graft-versus-host disease; Ig, immunoglobulin.
Chronic myelogenous leukemia in first chronic or accelerated phase, acute leukemia in first remission, refractory anemia, myelofibrosis.
Chronic myelogenous leukemia in blast crisis, acute leukemia beyond first remission, refractory anemia with excess blasts, lymphoma, multiple myeloma.
Typically, busulfan (approximately 16 mg/kg, targeted to 900 ng/mL) plus cyclophosphamide (120 mg/kg).
Cyclophosphamide (120 mg/kg) plus fractionated total body irradiation (12.0-13.2 Gy).
The patients conditioned with total marrow irradiation (9.0 Gy, fractionated) also received busulfan (approximately 14 mg/kg, targeted to 800 ng/mL) with or without cyclophosphamide (60 mg/kg).
Typically treated with prednisone (1-2 mg/kg/d per os [PO]) for 10-14 days, with subsequent tapering off over 50 days.
Typically treated with prednisone (0.5-1.0 mg/kg every other day PO) plus cyclosporine (approximately 6 mg/kg every other day PO) for at least 9 months.
For chronic myelogenous leukemia, the detection of bcr/abl transcript by polymerase chain reaction in the absence of cytogenetic or hematologic relapse was not considered a relapse.
Excluding patients who were treated with intravenous immunoglobulin within 2 months prior to the determination of the serum IgG level. The normal “range” in this study (5th-95th percentile) is 6.9-15.2 g/L.